Delivery Order SPE2DB22D3004-SPE2DB26FQ68S
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $7,389.26. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $8,606.93. The delivery order, issued on October 14, 2025, with an ultimate completion date of October 15, 2025, represents a non-competitive award under the company's existing contract vehicle with DLA. The place of performance is located at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $3,967.15 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packaging) with an ultimate completion date of August 19, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $1,664.71 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packages) on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ondansetron is a widely used anti-nausea medication commonly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) valued at $1,210.14 under a firm fixed price contract type. The award, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packages) under a firm fixed price contract valued at $28,394.05. The award was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be performed at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $3,430.80 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a $17,306.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packaging), with an ultimate completion date of September 5, 2025. This competitive award, issued on September 4, 2025, carries no set-aside designation and represents a single delivery order fulfilling pharmaceutical supply needs for federal medical procurement. The place of performance is listed as AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $6,047.25 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This competitive award, issued on June 20, 2025, with an ultimate completion date of June 23, 2025, represents a firm fixed price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB26FQ68SDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count) valued at $1,243.74, with an ultimate completion date of October 21, 2025. This delivery order represents a non-competitive, firm fixed-price transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen's comprehensive Pharmaceutical Prime Vendor Global Program contract (SPE2DX) with DLA Troop Support Medical, valued at approximately $1 billion through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor supporting the Defense Health Agency and broader military healthcare systems worldwide. The provision of Ondansetron, an antiemetic medication commonly used in clinical and surgical settings, reflects the company's role in supplying essential pharmaceutical products to support federal medical procurement needs across the Department of Defense healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 10/20/25 |